CU20200029A7 - Composición farmacéutica para el tratamiento de enfermedades respiratorias de origen viral - Google Patents

Composición farmacéutica para el tratamiento de enfermedades respiratorias de origen viral

Info

Publication number
CU20200029A7
CU20200029A7 CU2020000029A CU20200029A CU20200029A7 CU 20200029 A7 CU20200029 A7 CU 20200029A7 CU 2020000029 A CU2020000029 A CU 2020000029A CU 20200029 A CU20200029 A CU 20200029A CU 20200029 A7 CU20200029 A7 CU 20200029A7
Authority
CU
Cuba
Prior art keywords
ifn
treatment
pharmaceutical composition
respiratory diseases
type
Prior art date
Application number
CU2020000029A
Other languages
English (en)
Inventor
Rivero Iraldo Bello
Legrá Iván Campa
Roberts Yaquelin Duncan
Nieto Gerardo Enrique Guillén
Suárez Claudia Martínez
BLOMQUIST Dania Marcia VÁZQUEZ
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Priority to CU2020000029A priority Critical patent/CU20200029A7/es
Priority to PCT/CU2021/050003 priority patent/WO2021233484A1/es
Publication of CU20200029A7 publication Critical patent/CU20200029A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>Composición farmacéutica para el tratamiento de enfermedades respiratorias agudas de origen viral que comprende interferón (IFN) tipo I e IFN gamma donde la cantidad de IFN tipo I (UI) es entre 5 y 13 veces superior a la cantidad de IFN gamma (UI). Composición farmacéutica para el tratamiento de pacientes con persistencia de un virus que causa enfermedades respiratorias agudas que comprende IFN tipo I e IFN gamma donde la cantidad de IFN tipo I (UI) es entre 5 y 13 veces superior a la cantidad de IFN gamma (UI). La invención adicionalmente contempla la combinación de IFN tipo I (UI) y IFN gamma (UI) con otros antivirales.</p>
CU2020000029A 2020-05-20 2020-05-20 Composición farmacéutica para el tratamiento de enfermedades respiratorias de origen viral CU20200029A7 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CU2020000029A CU20200029A7 (es) 2020-05-20 2020-05-20 Composición farmacéutica para el tratamiento de enfermedades respiratorias de origen viral
PCT/CU2021/050003 WO2021233484A1 (es) 2020-05-20 2021-05-19 Composición farmaceutica para el tratamiento de enfermedades respiratorias de origen viral

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2020000029A CU20200029A7 (es) 2020-05-20 2020-05-20 Composición farmacéutica para el tratamiento de enfermedades respiratorias de origen viral

Publications (1)

Publication Number Publication Date
CU20200029A7 true CU20200029A7 (es) 2022-01-13

Family

ID=77338445

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000029A CU20200029A7 (es) 2020-05-20 2020-05-20 Composición farmacéutica para el tratamiento de enfermedades respiratorias de origen viral

Country Status (2)

Country Link
CU (1) CU20200029A7 (es)
WO (1) WO2021233484A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras

Also Published As

Publication number Publication date
WO2021233484A1 (es) 2021-11-25

Similar Documents

Publication Publication Date Title
CO2022011728A2 (es) Composiciones y usos de glp-1
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
MX2022016405A (es) Análogos de nucleósido de 1¿-ciano y usos de estos.
ES2186660T3 (es) Terapia de combinacion para erradicar hcv-rna detectable en pacientes con infeccion por hepatitis c cronica.
PH12020550051B1 (en) Glp-1 compositions and uses thereof
CL2022002481A1 (es) Compuestos antivirales y métodos para la administración de los mismos
MX369259B (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
PH12020551709A1 (en) Antiviral immunotropic agent for the treatment of acute respiratory viral infections
CO2021014024A2 (es) Métodos para tratar la distrofia muscular con casimersin
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
BR112015018259A2 (pt) Redução de resposta pró-inflamatória
MX2021003599A (es) Composiciones farmaceuticas que comprenden 9,10-dimetoxi-2-(2,4,6- trimetilfenilimino)-3-(n-carbamoil-2-aminoetil)-3,4,6,7-tetrahidr o-2h-pirimido[6,1-a]isoquinolin-4-ona (rpl554) en 1,1,1,2-tetrafluoroetano (hfa-134a) para administracion por inhalacion.
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
CU20200029A7 (es) Composición farmacéutica para el tratamiento de enfermedades respiratorias de origen viral
CO2020001322A2 (es) Tratamiento de hemorragia gastrointestinal en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante
CO2021002721A2 (es) Suspensiones líquidas de paracetamol
BR112022019679A2 (pt) Composição
BR112023019795A2 (pt) Composições nasais compreendendo alcaftadina
CL2022000990A1 (es) Combinación de un antagonista de cxcr7 con un modulador del receptor s1p1
AU2018324427A1 (en) Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics
AR080541A1 (es) Tratamiento para la endometriosis
Kannan et al. Coagulopathy in dengue fever patients
BR112021019979A2 (pt) Tratamento envolvendo interleucina-2 (il2) e interferon (ifn)
CL2024000431A1 (es) Contra enfermedades inflamatorias intestinales que involucra la disrupción del ensamblaje de heterómeros ccr9:drd5
BR112023026272A2 (pt) Combinação, composição farmacêutica, e, kit de partes